OCV Promotes Dr. Chris Bostick to General Partner

Aug 23, 2021 08:08 AM -08:00

OCV Partners (“OCV”) announced today that Dr. Chris Bostick has been promoted to General Partner.

Chris joined OCV in 2018 and has provided his expertise and leadership to all of our healthcare investments as well as contributing to many of our non-healthcare investments since joining OCV. Prior to joining OCV, Chris had a remarkable career as a scientist with broad interdisciplinary research experience including publication in top journals across Drug Metabolism, Physics, Neuroscience, and Chemistry. He conducted postdoctoral research at the Institute for Genomic Medicine at Columbia University where he studied precision medicine-based approaches for treating genetic neurological disorders. Chris earned his Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University where he completed research on drug metabolism, bioelectronics/biosensors, and nanotechnology. Chris holds a B.S. in Biology with a minor in Business from Cornell University. At OCV, Chris spearheads the diligence on the firm’s healthcare investments and has demonstrated a shrewd ability to back winning teams with three IPOs in his first three years as an investor.

“We are pleased that Chris accepted our offer to join our partnership. It is rare to find an established scientist that can so easily shift gears into an investor role,” said Hemi Zucker, Managing Partner at OCV. “Chris’ leadership skills have been invaluable to the firm and we expect him to continue excelling as our newest Partner.”

Chris’ investment portfolio and board involvement includes Precision Biosciences, Ossio (Board Observer), Finch Therapeutics, Praxis Precision Medicines, 1200 Pharma, TORL Biotherapeutics (Board Observer), ByHeart, and RadAI (Board Member).